COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic […]
Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence

Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients

For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And now, with the integration of AI into our data curation process, we have the potential to do data-assisted clinical research with more speed […]
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™

COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
Real-world data is helping to fine-tune care decisions for multiple myeloma patients: New research published at 2024 ASCO Annual Meeting

Researchers and clinicians agree that standards of care should be regularly reviewed and optimized based on the latest evidence to ensure that existing recommendations remain relevant.
Exploring standards of care in real-world settings with RWD

Real-world data (RWD) can help to illuminate patterns in therapy selection and the correlation to outcomes, giving oncologists and researchers some additional guidance on emerging trends in the oncology community.
From Data to Discovery: How AI Is Accelerating Progress in Oncology

the latest wave of data, technology, and artificial intelligence (AI) advances are challenging views, empowering individuals across life sciences functions to answer research questions using many different types of RWD
How COTA & Komodo Health Combine Real-World Datasets for Better Patient Insights

Komodo Health and COTA teamed up to link COTA’s high-quality oncology data with Komodo’s vast Healthcare MapTM